GC Biopharma Acquires Pipeline for Rare Coagulation Disease

GC Biopharma announced on Feb. 28 that it has signed an asset purchase agreement with Catalyst Biosciences, a US drug developer, for a pipeline for a coagulation disease.

Through this contract, GC Biopharma will acquire a total of three pipelines, including Marzeptacog alfa (MarzAA) under development in a global phase 3 clinical trial.

MarzAA has proven its effectiveness and safety in rare blood coagulation disorders through clinical development. Moreover, since MarzAA is being developed as a subcutaneous injection preparation, it can provide convenient administration to patients with rare coagulation disorders.

GC Biopharma explained that it plans to lay the foundation for entering global markets such as the United States and major developed countries by continuing the pipelines’ clinical trials with the goal of launching first-in-class drugs through the acquisition of the pipelines already in the clinical development stage in the United States.